HER2 in Breast Cancer
Author:
Annaratone Laura,Sarotto Ivana,Marchiò Caterina
Publisher
Springer International Publishing
Reference29 articles.
1. Arriola, E., Marchio, C., Tan, D. S., Drury, S. C., Lambros, M. B., Natrajan, R., Rodriguez-Pinilla, S. M., Mackay, A., Tamber, N., Fenwick, K., Jones, C., Dowsett, M., Ashworth, A., & Reis-Filho, J. S. (2008). Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory Investigation, 88, 491–503. 2. Ballard, M., Jalikis, F., Krings, G., Schmidt, R. A., Chen, Y. Y., Rendi, M. H., Dintzis, S. M., Jensen, K. C., West, R. B., Sibley, R. K., Troxell, M. L., & Allison, K. H. (2017). ‘Non-classical’ HER2 FISH results in breast cancer: A multi-institutional study. Modern Pathology, 30, 227–235. 3. Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., Ma, C. X., Ding, L., Mardis, E. R., & Ellis, M. J. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discovery, 3, 224–237. 4. Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., Bowlby, R., Shen, H., Hayat, S., Fieldhouse, R., Lester, S. C., Tse, G. M., Factor, R. E., Collins, L. C., Allison, K. H., Chen, Y. Y., Jensen, K., Johnson, N. B., Oesterreich, S., Mills, G. B., Cherniack, A. D., Robertson, G., Benz, C., Sander, C., Laird, P. W., Hoadley, K. A., King, T. A., Network, T. R., & Perou, C. M. (2015). Comprehensive molecular portraits of invasive lobular breast cancer. Cell, 163, 506–519. 5. Cocco, E., Javier Carmona, F., Razavi, P., Won, H. H., Cai, Y., Rossi, V., Chan, C., Cownie, J., Soong, J., Toska, E., Shifman, S. G., Sarotto, I., Savas, P., Wick, M. J., Papadopoulos, K. P., Moriarty, A., Cutler, R. E., Jr., Avogadri-Connors, F., Lalani, A. S., Bryce, R. P., Chandarlapaty, S., Hyman, D. M., Solit, D. B., Boni, V., Loi, S., Baselga, J., Berger, M. F., Montemurro, F., & Scaltriti, M. (2018). Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 11, pii: eaat9773.
|
|